Economic considerations of the treatment of ankylosing spondylitis

American Journal of the Medical Sciences

Volumn 343, Issue 5, 2012, Pages 371-374

  Reveille, John D ^a   Ximenes, Antonio ^b   Ward, Michael M ^c  

^a UNIVERSITY OF TEXAS   (United States)

^b Division of Rheumatology   (Brazil)

^c NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

Ankylosing spondylitis; Anti TNF treatment; Economics; Psoriatic arthritis; Spondyloarthritis

Indexed keywords

ETANERCEPT; INFLIXIMAB;

ANKYLOSING SPONDYLITIS; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEALTH CARE COST; HUMAN; LOW DRUG DOSE; PHYSIOTHERAPY; TOTAL HIP PROSTHESIS; TREATMENT DURATION;

EID: 84860796072     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e3182514093     Document Type: Conference Paper

References (42)

1. OECD. OECD Health Data 2008, "June 2008." Available at: www.oecd.org/dataoecd/42/57/36945724.pdf. Accessed July 15, 2011.
2. The Commonwealth Fund. 2008 Commonwealth Fund International Health Policy Survey of Sicker Adults. Available at: www.commonwealthfund.org/./Surveys/2008/ 2008-Commonwealth-Fund-International-Health-Policy-Survey-of-Sicker-Adults.aspx. Accessed July 15, 2011.
3. U.S. Census Bureau Current Population Survey 2008 and 2009 Annual Social and Economic Supplements. Available at: http://www.census.gov/prod/2009pubs/p60- 236.pdf. Accessed July 15, 2011.
4. Ward M. Functional disability predicts total costs in patients with ankylosing spondylitis. Arthritis Rheum 2002;46:223-31. (Pubitemid 34121668)
5. Boonen A, Brinkhuizen T, Landewé R, et al. Impact of ankylosing spondylitis on sick leave, presenteeism and unpaid productivity, and estimation of the societal cost. Ann Rheum Dis 2010;69:1123-8.
6. Boonen A, van der Heijde D, Landewé R, et al. Direct costs of ankylosing spondylitis and its determinants: an analysis among three European countries. Ann Rheum Dis 2003;62:732-40. (Pubitemid 36886407)
7. Franke LC, Ament AJ, van de Laar MA, et al. Cost-of-illness of rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 2009;27:S118-23.
8. Ara RM, Packham JC, Haywood KL. The direct healthcare costs associated with ankylosing spondylitis patients attending a UK secondary care rheumatology unit. Rheumatology (Oxford) 2008;47:68-71. (Pubitemid 350286265)
9. Kobelt G, Sobocki P, Mulero J, et al. The burden of ankylosing spondylitis in Spain. Value Health 2008;11:408-15. (Pubitemid 351712968)
10. Strömbeck B, Englund M, Bremander A, et al. Cost of illness from the public payers' perspective in patients with ankylosing spondylitis in rheumatological care. J Rheumatol 2010;37:2348-55.
11. Mould-Quevedo J, Peláez-Ballestas I, Vázquez-Mellado J, et al. Social costs of the most common inflammatory rheumatic diseases in Mexico from the patient's perspective. Gac Med Mex 2008;144: 225-31.
12. Torres TM, Ferraz MB, Ciconelli RM. Resource utilisation and cost of ankylosing spondylitis in Brazil. Clin Exp Rheumatol 2010; 28:490-7.
13. Younes M, Jalled A, Aydi Z, et al. Socioeconomic impact of anky-losing spondylitis in Tunisia. Joint Bone Spine 2010;77:41-6.
14. Zhu TY, Tam LS, Lee VW, et al. Costs and quality of life of patients with ankylosing spondylitis in Hong Kong. Rheumatology (Oxford) 2008;47:1422-5.
15. van der Heijde D, Sieper J, Maksymowych WP, et al; Assessment of SpondyloArthritis International Society. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 2011;70:905-8.
16. Neilson AR, Sieper J, Deeg M. Cost-effectiveness of etanercept in patients with severe ankylosing spondylitis in Germany. Rheumatology (Oxford) 2010;49:2122-34.
17. Kobelt G, Sobocki P, Mulero J, et al. The cost-effectiveness of infliximab in the treatment of ankylosing spondylitis in Spain. Comparison of clinical trial and clinical practice data. Scand J Rheumatol 2008; 37:62-71.
18. Boonen A, van der Heijde D, Severens JL, et al. Markov model into the cost-utility over 5 years of etanercept and infliximab compared to usual care in patients with active ankylosing spondylitis. Arthritis Rheum Dis 2006;65:201-8. (Pubitemid 43131994)
19. McLeod C, Bagust A, Boland A, et al. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation. Health Technol Assess 2007;11:1-158.
20. Maksymowych WP, Gooch KL, Wong RL, et al. Impact of age, sex, physical function, health-related quality of life, and treatment with adalimumab on work status and work productivity in patients with ankylosing spondylitis. J Rheumatol 2010;37:385-92.
21. Barkham N, Coates LC, Keen H, et al. Double-blind placebo-controlled trial of etanercept in the prevention of work disability in ankylosing spondylitis. Ann Rheum Dis 2010;69:1926-8.
22. Fautrel B, Benhamou M, Breban M, et al. Cost effectiveness of two therapeutic regimens of infliximab in ankylosing spondylitis: economic evaluation within a randomised controlled trial. Ann Rheum Dis 2010; 69:424-7.
23. Sidiropoulos P, Kritikos HD, Siakka P, et al. Low dose of infliximab is inadequate in most patients with spondylarthropathies. Clin Exp Rheumatol 2005;23:513-6. (Pubitemid 41447623)
24. Jois RN, Leeder J, Gibb A, et al. Low-dose infliximab treatment for ankylosing spondylitis\clinically-and cost-effective. Rheumatology (Oxford) 2006;45:1566-9. (Pubitemid 44817066)
25. Inman RD, Maksymowych WP; CANDLE Study Group. A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis. J Rheumatol 2010;37:1203-10.
26. Tenga G, Goëb V, Lequerré T, et al. A 3 mg/kg starting dose of infliximab in active spondyloarthritis resistant to conventional treatments is efficient, safe and lowers costs. Joint Bone Spine 2011;78:50-5.
27. Navarro-Compán V, Moreira V, Ariza-Ariza R, et al. Low doses of etanercept can be effective in ankylosing spondylitis patients who achieve remission of the disease. Clin Rheumatol 2011;30:993-6.
28. Lee SH, Lee YA, Hong SJ, et al. Etanercept 25 mg/week is effective enough to maintain remission for ankylosing spondylitis among Korean patients. Clin Rheumatol 2008;27:179-81.
29. Moghimi J, Sheikhvatan M, Semnani V. The use of low-dose etaner-cept as an alternative therapy for treatment of ankylosing spondylitis: a case series [published online ahead of print May 8, 2011]. Rheumatol Int doi: 10.1007/s00296-011-1920-0.
30. Brandt J, Listing J, Haibel H, et al. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. Rheumatology 2005;44:342-8. (Pubitemid 40361291)
31. Baraliakos X, Listing J, Brandt J, et al. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther 2005;7:R439-44.
32. Sweeney S, Gupta R, Taylor G, et al. Total hip arthroplasty in ankylos-ing spondylitis: outcome in 340 patients. J Rheumatol 2001;28:1862-6. (Pubitemid 32726935)
33. Vander Cryssen B, Muñoz-Gomariz E, Font P, et al. Hip involvement in ankylosing spondylitis: epidemiology and risk factors associated with hip replacement surgery. Rheumatology 2010;49:73-81.
34. Sochart DH, Porter ML. Long-term results of total hip replacement in young patients who had ankylosing spondylitis. Eighteen to thirty-year results with survivorship analysis. J Bone Joint Surg Am 1997;79: 1181-9. (Pubitemid 27365025)
35. Joshi AB, Markovic L, Hardinge K, et al. Total hip arthroplasty in ankylosing spondylitis: an analysis of 181 hips. J Arthroplasty 2002;17: 427-33. (Pubitemid 34663259)
36. Verstrappen SM, Jacobs JW, van der Heijde DM, et al. Utility and direct costs: ankylosing spondylitis compared with rheumatoid arthritis. Ann Rheum Dis 2007;66:727-31. (Pubitemid 46846690)
37. Dagfinrud H, Kvien TK, Hagen KB. Physiotherapy interventions for ankylosing spondylitis. Cochrane Database Syst Rev 2008;23: CD002822.
38. Masiero S, Bonaldo L, Paigatto M, et al. Rehabilitation treatment in patients with ankylosing spondylitis stabilized with tumor necrosis factor inhibitor therapy: a randomized controlled trial. J Rheumatol 2011;38:1335-42.
39. Uhrin Z, Kuzis S, Ward MM. Exercise and changes in health status in patients with ankylosing spondylitis. Arch Intern Med 2000;160:2969-75. (Pubitemid 32009055)
40. Boonen A. A review of work participation, cost-of-illness and cost-effectiveness studies in ankylosing spondylitis. Nat Clin Prac Rheumatol 2006;2:546-53. (Pubitemid 44489958)
41. Ward MM, Kuzis S. Risk factors for work disability in patients with ankylosing spondylitis. J Rheumatol 2001;28:315-21. (Pubitemid 32165140)
42. Ward MM, Reveille JD, Learch TJ, et al. Impact of ankylosing spondylitis on work and family life: comparisons with the U.S. population. Arthritis Rheum 2008;59:497-503. (Pubitemid 351563531)